Daneshvar-Ghahfarokhi Shole, Ahmadinia Hassan, Sadeghi Tabandeh, Basirat Elham, Mohammadi-Shahrokhi Vahid
Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Department of Epidemiology and Biostatistics, School of Health, Occupational Environment Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
BMC Nutr. 2025 Jan 24;11(1):21. doi: 10.1186/s40795-025-01005-5.
The therapeutic properties of Achillea Millefolium (AM) in regulating blood lipids and liver enzymes have been proven in studies. Considering the abnormal lipid levels and elevated liver enzymes in diabetic patients, this study was conducted to investigate the effect of AM on the lipid profile and serum level of liver enzymes in type 2 diabetic (T2D) patients.
In this 90-day double-blind clinical trial study, 60 eligible diabetic patients were enrolled and divided into intervention and control (each 30 patients) groups. The intervention group received AM capsules (dose of 500 mg/day) for 3 months, and the control group received placebo capsules during the same period. Blood was taken from patients on day 0 and day 90. The serum levels of liver enzymes and lipid profiles of patients were measured at baseline and on day 90. The obtained values were analyzed and compared between two control and treatment groups and within each group.
AM oral supplementation caused a significant decrease in alanine aminotransferases (ALT; from 28.79 ± 10.99 to 24.41 ± 6.84, p = 0.017) and aspartate aminotransferases (AST; from 24.28 ± 7.91 to 18.76 ± 6.77, p = 0.007). A significant reduction in the levels of serum lipids such as triglyceride (TG; from 161.7 ± 77.18 to 147.3 ± 66.79, p = 0.045), low-density lipoprotein (LDL; from 98.90 ± 35.67 to 80.86 ± 32.10, p = 0.001), and total cholesterol (TC; from 168.3 ± 47.46 to 150.1 ± 38.77, p = 0.006) was noted in AM group. According to these results, after the intervention, the mean of all variables (except HDL) in the two groups had a significant difference (P < 0.05).
The study showed that the 3-month treatment of T2D patients with 500 mg/day AM capsules led to the reduction of liver enzymes and the regulation of blood lipids in them.
Iranian Registry of Clinical Trials IRCT20230612058459N1 Registered on 2023-06-24.
研究已证实蓍草在调节血脂和肝脏酶方面具有治疗特性。考虑到糖尿病患者血脂异常和肝脏酶升高，本研究旨在探讨蓍草对2型糖尿病（T2D）患者血脂谱和血清肝脏酶水平的影响。
在这项为期90天的双盲临床试验研究中，60名符合条件的糖尿病患者被纳入并分为干预组和对照组（每组30名患者）。干预组服用蓍草胶囊（剂量为500毫克/天），持续3个月，对照组在同一时期服用安慰剂胶囊。在第0天和第90天采集患者血液。在基线和第90天测量患者的血清肝脏酶水平和血脂谱。对获得的值在两个对照组和治疗组之间以及每组内部进行分析和比较。
口服蓍草导致丙氨酸转氨酶（ALT；从28.79±10.99降至24.41±6.84，p = 0.017）和天冬氨酸转氨酶（AST；从24.28±7.91降至18.76±6.77，p = 0.007）显著降低。蓍草组的甘油三酯（TG；从161.7±77.18降至147.3±66.79，p = 0.045）、低密度脂蛋白（LDL；从98.90±35.67降至80.86±32.10，p = 0.001）和总胆固醇（TC；从168.3±47.46降至150.1±38.77，p = 0.006）等血清脂质水平显著降低。根据这些结果，干预后两组中所有变量（高密度脂蛋白除外）的平均值有显著差异（P < 0.05）。
该研究表明，每天500毫克蓍草胶囊对T2D患者进行3个月治疗可降低其肝脏酶水平并调节血脂。
伊朗临床试验注册中心IRCT20230612058459N1，于2023年6月24日注册。
